Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Recruiting · NCT03755193 · Interventional (participants receive a specific treatment) · Lead sponsor: Shinshu University
View the official record on ClinicalTrials.gov →Interventions studied
Bisphosphonates and ELD "Edirol®Tablet 0.75ug"ELD "Edirol®Tablet 0.75ug"SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
What this trial is about
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months
Who can take part
Age range
20 Years to 120 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- osteoporosis patients
Exclusion criteria
- not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant
Where it is running
1 location listed.
- Yukio Nakamura - Matsumoto, Nagano, Japan